Resumen
Las hepatitis víricas constituyen la causa más frecuente de hepatitis aguda y crónica a nivel mundial. El diagnóstico de los virus hepatotropos es serológico. El tratamiento de la hepatitis C se realiza mediante antivirales de acción directa. Las indicaciones de tratamiento en la hepatitis B se basan en parámetros analíticos y métodos no invasivos. No existe un tratamiento específico para el virus de la hepatitis A y en la hepatitis crónica por hepatitis E se administra ribavirina.
Palabras clave
Virus de la hepatitis
Diagnóstico
Tratamiento
Abstract
Viral hepatitis is the most common cause of acute and chronic hepatitis worldwide. Hepatotropic viruses are diagnosed serologically. Hepatitis C is treated with direct-acting antivirals. The indications for hepatitis B treatment are based on analytical parameters and non-invasive methods. There is no specific treatment for hepatitis A virus. In chronic hepatitis E, ribavirin is administered.
Keywords
Hepatitis virus
Diagnosis
Treatment
Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1]
M. Rodríguez , M. Buti, R. Esteban, S. Lens, M. Prieto, E. Suárez, et al.
Documento de consenso de la Asociación Española para el Estudio del Hígado sobre el tratamiento de la infección por el virus de la hepatitis B (2020).
Gastroenterol Hepatol., (2020), 43 pp. 559-587
[2]
M. Chayanupatkul , R. Omino, S. Mittal, J.R. Kramer, P. Richardson, A.P. Thrift, et al.
Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
J Hepatol., (2017), 66 pp. 355-362
[3]
J. Liu , H.I. Yang, M.H. Lee, S.N. Lu, C.L. Jen, L.Y. Wang, et al.
REVEAL-HBV Study Group. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.
Gastroenterology., (2010), 139 pp. 474-482
[4]
M. Viganò , S. Paggi, P. Lampertico, M. Fraquelli, S. Massironi, G. Ronchi, et al.
Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation.
Aliment Pharmacol Ther., (2011), 34 pp. 353-362
[5]
Evaluation of antiviral therapy performed after curative therapy in patients with hbv-related hepatocellular carcinoma: An updated meta-analysis.
Can J Gastroenterol Hepatol., (2016), 2016 pp. 5234969
[6]
EASL 2017. Clinical practice guidelines on the management of hepatitis B virus infection.
J Hepatol., (2017), 67 pp. 370-398
[7]
E.S. Park , A.R. Lee, D.H. Kim, J.H. Lee, J.J. Yoo, S.H. Ahn, et al.
Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
J Hepatol., (2019), 70 pp. 1093-1102
[8]
G.L. Wong , Y.K. Tse, V.W. Wong, T.C. Yip, K.K. Tsoi, H.L. Chan.
Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects.
Hepatology., (2015), 62 pp. 684-693
[9]
M. Riveiro-Barciela , D. Tabernero, J.L. Calleja, S. Lens, M.L. Manzano, F.G. Rodríguez, et al.
Effectiveness and safety of entecavir or tenofovir in a spanish cohort of chronic hepatitis b patients: validation of the page-b score to predict hepatocellular carcinoma.
Dig Dis Sci., (2017), 62 pp. 784-793
[10]
P. Marcellin , E. Gane, M. Buti, N. Afdhal, W. Sievert, I.M. Jacobson, et al.
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Lancet., (2013), 381 pp. 468-475
[11]
S. Rodríguez-Nóvoa , J. García-Samaniego, M. Prieto, J.L. Calleja, J.M. Pascasio, M. Delgado Blanco, et al.
MENTE Study Group. Altered underlying renal tubular function in patients with chronic hepatitis b receiving nucleos(t)ide analogs in a real-world setting: The MENTE Study.
J Clin Gastroenterol., (2016), 50 pp. 779-789
[12]
Epidemiology and management of hepatocellular carcinoma.
Gastroenterology., (2019), 156
[13]
F. Goehringer , F. Bonnet, D. Salmon, P. Cacoub, A. Paye, G. Chêne, et al.
Causes of death in HIV-infected individuals with immunovirologic success in a national prospective survey.
AIDS Res Hum Retroviruses., (2017), 33 pp. 187-193
[14]
M. Pérez-Olmeda , M. Núñez, J. García-Samaniego, P. Ríos, J. González-Lahoz, V. Soriano.
Distribution of hepatitis B virus genotypes in HIV-infected patients with chronic hepatitis B: therapeutic implications.
AIDS Res Hum Retroviruses., (2003), 19 pp. 657-659
[15]
The spectrum of HBV/HCV coinfection: Epidemiology, clinical characteristics, viral interactions and management.
Ann Gastroenterol., (2015), 28 pp. 221-228
[16]
A. De Monte , J. Courjon, R. Anty, E. Cua, A. Naqvi, V. Mondain, et al.
Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
J Clin Virol., (2016), 78 pp. 27-30
[17]
N.A. Terrault , A.S.F. Lok, B.J. McMahon, K.M. Chang, J.P. Hwang, M.M. Jonas, et al.
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 Hepatitis B Guidance.
Clin Liver Dis (Hoboken)., (2018), 12 pp. 33-34
[18]
Immunosuppression and HBV reactivation.
Semin Liver Dis., (2013), 33 pp. 167-177
[19]
Hepatitis treatment: The challenges of hepatitis B reactivation: The controversies continue.
Dig Dis., (2017), 35 pp. 351-358
[20]
Reactivation of hepatitis B associated with immunosuppressants and chemotherapy: Natural history, risk factors and recommendations for prevention.
Med Clin (Barc)., (2019), 152 pp. 107-114
[21]
E. Cholongitas , A.B. Haidich, F. Apostolidou-Kiouti, P. Chalevas, G.V. Papatheodoridis.
Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review.
Ann Gastroenterol., (2018), 31 pp. 480-490
[22]
American Gastroenterological Association Institute Technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
Gastroenterology., (2015), 148 pp. 221-244
[23]
A.J. Stockdale , B. Kreuels, M.Y.R. Henrion, E. Giorgi, I. Kyomuhangi, C. de Martel, et al.
The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis.
J Hepatol., (2020), 73 pp. 523-532
[24]
H. Wedemeyer , C. Yurdaydìn, G.N. Dalekos, A. Erhardt, Y. Çakaloğlu, H. Değertekin, et al.
HIDIT Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta.
N Engl J Med., (2011), 364 pp. 322-331
[25]
Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018.
J Hepatol., (2018), 69 pp. 461-511
[28]
J.M. Pascasio , C. Vinaixa, M.T. Ferrer, J. Colmentero, A. Rubin, L. Castells, et al.
Clinical outcoems of patients undergoing antiviral therapy while awaiting liver transplantation.
J Hepatol., (2017), 67 pp. 1168-1176
[29]
Infect Dis Clin North Am., (2000), 14 pp. 605
[30]
R.M. Taylor , T. Davern, S. Muñoz, S.H. Han, B. McGuire, A.M. Larson, et al.
US Acute Liver Failure Study Group. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes.
Hepatology., (2006), 44 pp. 1589-1597
[31]
H.R. Dalton , N. Kamar, J.J. van Eijk, B.N. McLean, P. Cintas, R.P. Bendall, et al.
Hepatitis E virus and neurological injury.
Nat Rev Neurol., (2016), 12 pp. 77-85
